Aiming To Join The Top 10
Pharmaceutical Companies
With
An Average Annual Growth Rate Of 13%.
*Disclosure Standards
- 0bn
KRW2019 - 0bn
KRW2020 - 0bn
KRW2021 - 0bn
KRW2022 - 0bn
KRW2023 - 0bn
KRW2024
Daewoong Bio Is A Forward-Thinking
And Ambitious Company.
Grade By Field*As of 2025
CNS(Central Nervous System)
1Rank
CSO(Contract Sales Organization)
1Rank
No.1 CNS Market236.9billion(M/S 10.4%)
*As of 2025Gliatamin176.1billion(M/S 31.8%)
1Rank
Beacept Generic34.9billion(M/S 10.2%)
2Rank
Sales Growth*As of 2024
Annual Revenue
5,795billion
wonOperating Profit
804billion
won
Global UDCA and
Bio Exports
28countries and beyond
Continuous global expansion,
connecting to the world in real time.
Daewoong Bio Moves Forward
With A Pioneering Spirit,
Beyond Limits.
- Founded In 1983
A Trusted Daewoong Pharma Affiliate
With
Over 40 Years Of Expertise. - 2024’s Sales
Achieved KRW 579.6B In 2024,
Proving Industry Competitiveness. - 4 Production Facilities
Stable Global Supply Through 4 domestic
And
Overseas Production Sites. - 520 Employees
Around 520 Talented Professionals
Growing Together
With Expertise And
Passion.
State-of-the-art global facilities
ensure quality
and process efficiency.
Korea’s Largest Biologics Facility
BIO CENTERThe new Daewoong BIO CENTER specializes
in
microbial recombinant biologics with
advanced manufacturing.
With 1,000 L fermenters, automated flow systems,
and
finished-dose lines, it provides end-to-end
CDMO support.
Meeting global standards, it serves as a key hub
for
biotech growth and global expansion.
Securing Antibiotics for Health
CEPHA CENTERDaewoong Bio is building a new CEPHA CENTER
in Hwaseong
with a KRW 55 billion investment to
secure antibiotic supply.
Completion is set for May 2025,
with GMP
certification and production targeted for December.
The facility meets advanced GMP standards
and reflects the latest aseptic regulations.
Global UDCA No.1
API CENTERThe API CENTER produces major APIs like UDCA
and Fexuprazan,
serving as a core hub for
Daewoong Bio.
Its top-down flow system and optimized HVAC
minimize contamination and ensure strict
quality control.
Built to CGMP and EU-GMP standards,
it has secured multiple global certifications.
Proven Quality
ANSEONG CENTERThe Anseong Center produces about 400 million
tablets annually and
serves as a key hub for stable
supply. Focusing on CNS and metabolic drugs,
it continues to enhance quality and
competitiveness.
With strict management and ongoing facility
upgrades,
it meets evolving regulations and market
needs while
maintaining global-standard quality.
